Profusa Inc (PFSA)

$0.45 -0.03 (-7.09%)
Market Cap 2.12M
Revenue (ttm) 0.00
Net Income (ttm) -35.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.51
Volume 247,000
Avg Vol 5,998,032
Day's Range N/A - N/A
Shares Out 4.41M
Stochastic %K 5%
Beta 0.47
Analysts Strong Buy
Price Target N/A

Company Profile

Profusa, Inc. develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.

Industry: Medical Devices
Sector: Healthcare
Phone: 925 997 6925
Website: profusa.com
Address:
626 Bancroft Way, Suite A, Berkeley, United States
Nuclear_Elvis
Nuclear_Elvis May. 12 at 5:20 PM
$PFSA At this rate, PFSA is near guaranteed to receive a delisting notice for the downgraded NASDAQ CM market they are now listed on, as Profusa must maintain at least a $5 Million Market Cap to remain listed and that deadline is July 2026. I don't see the stock gaining and sustaining a 150% price increase before then. Current Market Cap for PFSA is hovering around $2 Million.
0 · Reply
alby777
alby777 May. 11 at 7:42 PM
$PFSA Conclusion: While the company is looking at "strategic alternatives" (which usually implies a potential sale), they are simultaneously attempting to make their own acquisitions and are in a precarious financial position, making a buyout one of many potential outcomes, rather than a confirmed one.
0 · Reply
Hydrojim
Hydrojim May. 8 at 8:38 PM
$PFSA
0 · Reply
stopping
stopping May. 8 at 5:45 PM
$PFSA fda진행상황 알고 계신분 있으신가요.?
0 · Reply
MicsMugz
MicsMugz May. 8 at 5:15 PM
$GCTK $PFSA
0 · Reply
Nuclear_Elvis
Nuclear_Elvis May. 8 at 1:44 PM
$PFSA Reality of today's news for Profusa - it is a downgrade in market listing (NASDAQ GM TO CM) rather than delistIng, but delisting is still likely. New NASDAQ rule as of this month (May 2026), must retain $5M Market Cap to remain listed in NASDAQ CM. While it is a $15M Market Cap minimum to enter, you only get a downside to $5M to be forced out. Downgrades from GM to CM are not initial entry, which is why Profusa is lucky to simply be downgraded, BUT the CM rules for remaining listed still apply (and must be met by July '26), and PFSA has less than $3M Market Cap as of today. The company has or will dilute the stock, and the Market Cap will change based on that new number of Outstanding shares, but diluting to meet Market Cap listing requirements doesn't normally work out so well. The announcement of "exploring strategic alternatives" (i.e. company is open to being sold or merged) - makes more sense, as it is desperation before future delisting, and a way to hype the stock.
0 · Reply
showme809
showme809 May. 8 at 11:45 AM
$PFSA Can they do it by July 6?
0 · Reply
focafoca99
focafoca99 May. 8 at 10:26 AM
$PFSA received a Nasdaq listing determination approving its move to the Capital Market tier.
0 · Reply
focafoca99
focafoca99 May. 8 at 10:18 AM
$PFSA has been granted a Nasdaq listing exception subject to compliance milestones.
0 · Reply
ShadowSnake
ShadowSnake May. 7 at 4:45 PM
$PFSA any hope left?
0 · Reply
Latest News on PFSA
Profusa receives favorable Nasdaq listing determination

2026-05-08T10:07:48.000Z - 5 days ago

Profusa receives favorable Nasdaq listing determination

Profusa Receives Favorable Nasdaq Listing Determination

May 8, 2026, 6:00 AM EDT - 5 days ago

Profusa Receives Favorable Nasdaq Listing Determination

Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value

May 5, 2026, 8:30 AM EDT - 7 days ago

Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value

Profusa announces $30M letter of intent for PanOmics diagnostic platform

2026-04-06T10:05:05.000Z - 5 weeks ago

Profusa announces $30M letter of intent for PanOmics diagnostic platform

Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform

Apr 6, 2026, 6:00 AM EDT - 5 weeks ago

Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform

Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering

Feb 27, 2026, 9:15 AM EST - 2 months ago

Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering

Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance

Feb 19, 2026, 8:30 AM EST - 2 months ago

Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance

Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies

Feb 13, 2026, 8:30 AM EST - 3 months ago

Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies

Profusa Announces 1-for-75 Reverse Stock Split

Feb 5, 2026, 8:00 AM EST - 3 months ago

Profusa Announces 1-for-75 Reverse Stock Split

Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026

Jan 29, 2026, 8:00 AM EST - 3 months ago

Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026

Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue

Jan 16, 2026, 7:30 AM EST - 4 months ago

Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue

Profusa Adds Leading Greek Vascular Surgeon to Customer Base

Jan 8, 2026, 7:30 AM EST - 4 months ago

Profusa Adds Leading Greek Vascular Surgeon to Customer Base

Profusa Bolsters European Commercial Network with New French Distributor, MedSell

Dec 31, 2025, 7:30 AM EST - 4 months ago

Profusa Bolsters European Commercial Network with New French Distributor, MedSell

Here’s Why Profusa Stock (PFSA) Rocketed Today

2025-12-30T14:56:15.000Z - 4 months ago

Here’s Why Profusa Stock (PFSA) Rocketed Today

Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35

Dec 30, 2025, 7:30 AM EST - 4 months ago

Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35

Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025

Dec 15, 2025, 7:30 AM EST - 5 months ago

Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025

Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026

Dec 11, 2025, 8:30 AM EST - 5 months ago

Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026

Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025

Nov 24, 2025, 8:15 AM EST - 6 months ago

Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025

Profusa Announces Third Quarter Business and Financial Highlights

Nov 19, 2025, 5:44 PM EST - 6 months ago

Profusa Announces Third Quarter Business and Financial Highlights

Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee™ Oxygen and Glucose Monitoring Launches

Oct 30, 2025, 7:30 AM EDT - 6 months ago

Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee™ Oxygen and Glucose Monitoring Launches

Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026

Oct 28, 2025, 8:30 AM EDT - 7 months ago

Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026

Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in Europe

Oct 22, 2025, 8:30 AM EDT - 7 months ago

Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in Europe

Profusa Invests Additional $1 Million in Digital Treasury Assets

Oct 7, 2025, 8:15 AM EDT - 7 months ago

Profusa Invests Additional $1 Million in Digital Treasury Assets

Profusa Adds a Leading French Critical Limb Ischemia Surgeon to Customer Base

Oct 1, 2025, 8:30 AM EDT - 7 months ago

Profusa Adds a Leading French Critical Limb Ischemia Surgeon to Customer Base

Profusa Adopts NVIDIA-Powered Technology to Build AI-Driven Insight Portal for Continuous Biomarker Monitoring

Sep 11, 2025, 8:30 AM EDT - 8 months ago

Profusa Adopts NVIDIA-Powered Technology to Build AI-Driven Insight Portal for Continuous Biomarker Monitoring

Profusa Adds Head of Vascular Surgery Department at AZ Sint Blasius Hospital, Belgium to Growing Customer Base

Sep 4, 2025, 8:30 AM EDT - 8 months ago

Profusa Adds Head of Vascular Surgery Department at AZ Sint Blasius Hospital, Belgium to Growing Customer Base

Profusa Announces Commercial and Clinical Collaboration with Head of Angiography, Medical University of Graz, Austria

Aug 27, 2025, 8:45 AM EDT - 9 months ago

Profusa Announces Commercial and Clinical Collaboration with Head of Angiography, Medical University of Graz, Austria

Profusa Welcomes Former Acting U.S. Veterans Affairs Secretary Peter O'Rourke as Lead Independent Director; Adds Seasoned Finance Executive Fred Knechtel as CFO

Aug 19, 2025, 8:15 AM EDT - 9 months ago

Profusa Welcomes Former Acting U.S. Veterans Affairs Secretary Peter O'Rourke as Lead Independent Director; Adds Seasoned Finance Executive Fred Knechtel as CFO

Profusa, Inc. Provides Strategy Overview and Business Update for Investors

Aug 6, 2025, 8:15 AM EDT - 9 months ago

Profusa, Inc. Provides Strategy Overview and Business Update for Investors

Profusa Secures Lumee™ Oxygen Platform Distributor in Spain

Jul 31, 2025, 8:15 AM EDT - 10 months ago

Profusa Secures Lumee™ Oxygen Platform Distributor in Spain

Profusa Announces $100 Million Equity Line of Credit to Initiate Bitcoin Treasury Strategy

Jul 21, 2025, 8:00 AM EDT - 10 months ago

Profusa Announces $100 Million Equity Line of Credit to Initiate Bitcoin Treasury Strategy

Profusa Announces Closing of Business Combination and the Commencement of Trading on Nasdaq

Jul 11, 2025, 4:00 PM EDT - 10 months ago

Profusa Announces Closing of Business Combination and the Commencement of Trading on Nasdaq

Nuclear_Elvis
Nuclear_Elvis May. 12 at 5:20 PM
$PFSA At this rate, PFSA is near guaranteed to receive a delisting notice for the downgraded NASDAQ CM market they are now listed on, as Profusa must maintain at least a $5 Million Market Cap to remain listed and that deadline is July 2026. I don't see the stock gaining and sustaining a 150% price increase before then. Current Market Cap for PFSA is hovering around $2 Million.
0 · Reply
alby777
alby777 May. 11 at 7:42 PM
$PFSA Conclusion: While the company is looking at "strategic alternatives" (which usually implies a potential sale), they are simultaneously attempting to make their own acquisitions and are in a precarious financial position, making a buyout one of many potential outcomes, rather than a confirmed one.
0 · Reply
Hydrojim
Hydrojim May. 8 at 8:38 PM
$PFSA
0 · Reply
stopping
stopping May. 8 at 5:45 PM
$PFSA fda진행상황 알고 계신분 있으신가요.?
0 · Reply
MicsMugz
MicsMugz May. 8 at 5:15 PM
$GCTK $PFSA
0 · Reply
Nuclear_Elvis
Nuclear_Elvis May. 8 at 1:44 PM
$PFSA Reality of today's news for Profusa - it is a downgrade in market listing (NASDAQ GM TO CM) rather than delistIng, but delisting is still likely. New NASDAQ rule as of this month (May 2026), must retain $5M Market Cap to remain listed in NASDAQ CM. While it is a $15M Market Cap minimum to enter, you only get a downside to $5M to be forced out. Downgrades from GM to CM are not initial entry, which is why Profusa is lucky to simply be downgraded, BUT the CM rules for remaining listed still apply (and must be met by July '26), and PFSA has less than $3M Market Cap as of today. The company has or will dilute the stock, and the Market Cap will change based on that new number of Outstanding shares, but diluting to meet Market Cap listing requirements doesn't normally work out so well. The announcement of "exploring strategic alternatives" (i.e. company is open to being sold or merged) - makes more sense, as it is desperation before future delisting, and a way to hype the stock.
0 · Reply
showme809
showme809 May. 8 at 11:45 AM
$PFSA Can they do it by July 6?
0 · Reply
focafoca99
focafoca99 May. 8 at 10:26 AM
$PFSA received a Nasdaq listing determination approving its move to the Capital Market tier.
0 · Reply
focafoca99
focafoca99 May. 8 at 10:18 AM
$PFSA has been granted a Nasdaq listing exception subject to compliance milestones.
0 · Reply
ShadowSnake
ShadowSnake May. 7 at 4:45 PM
$PFSA any hope left?
0 · Reply
alby777
alby777 May. 7 at 4:01 PM
$PFSA This Insider is Buying PFSA shares! https://app.quotemedia.com/data/downloadFiling?webmasterId=131029&ref=320019950&type=HTML
0 · Reply
alby777
alby777 May. 7 at 3:01 PM
$PFSA Based on recent SEC filings, Jack E. Stover, a director for Profusa, Inc. (PFSA), has been involved in transactions involving PFSA shares in 2026.Stock Option Grants (Jan 2026): On January 26, 2026, Stover was reported to have received grants to purchase 221,794 shares of common stock."Purchase" Transactions (Jan 2026): Market reports indicate that on January 26, 2026, Stover (listed as a director) was involved in a transaction with 553,665 shares.Entity Transactions (May 2026): Reports indicate that on May 6, 2026, a director-related entity, NorthView Sponsor I LLC, was involved in converting notes to shares... Bullish? M&A?
0 · Reply
alby777
alby777 May. 6 at 11:48 PM
$PFSA Big Insider Buy! https://app.quotemedia.com/data/downloadFiling?webmasterId=131029&ref=320019950&type=HTML
0 · Reply
Hydrojim
Hydrojim May. 6 at 5:16 PM
$PFSA i got a feva, and the only prescription is more profusa...
0 · Reply
alby777
alby777 May. 6 at 4:07 PM
$PFSA Insider Buys Big! In SEC Form 4 filings, code P stands for a Purchase. It indicates an insider bought company shares on the open market or in a private transaction using their own money. This is viewed by investors as a strong, bullish "conviction" signal that management believes the stock price will rise... https://app.quotemedia.com/data/downloadFiling?webmasterId=131029&ref=320019950&type=HTML
0 · Reply
Amateur_trader01
Amateur_trader01 May. 6 at 2:43 PM
$PFSA
0 · Reply
Nuclear_Elvis
Nuclear_Elvis May. 6 at 2:38 PM
$PFSA The Board has decided to put the company up for sale. Looks like they are also tired of Dr. Hwang leading the company. Time for someone else to take charge of the future of Profusa.
1 · Reply
alby777
alby777 May. 5 at 6:02 PM
$TROO $WLGS (Ticker $WLGSF @ $0.007) BUY!!? M&A? $SOFI $ATCH $PFSA (M&A news pending?) https://www.wangnleegroup.com/post/wang-lee-group-invests-troops-smart-building-esg-token
0 · Reply
alby777
alby777 May. 5 at 5:48 PM
$PFSA Tungsten Advisors is a New York-based investment banking firm founded in 2019 that specializes in strategic advisory, capital raising, and mergers and acquisitions (M&A) for the healthcare and technology sectors. They provide tailored financial solutions, including private placements and corporate licensing, and are known for acting as agents in financing deals. Tungsten Advisors specializes in life sciences, biotechnology, and technology industries. Services: Transactional services including M&A, private placements/PIPEs, and corporate licensing. The firm operates as a merchant bank or advisor, often involved in emerging growth companies.Affiliation: Securities are offered through Finalis Securities LLC, a member of FINRA/SIPC.Team Expertise: The firm is led by professionals with extensive backgrounds in investment banking and sector-specific knowledge. https://www.tungstenadv.com/
0 · Reply
alby777
alby777 May. 5 at 5:40 PM
$PFSA 85 Global patents granted or pending, backed by 100 $MILLION + in investment including $30 Million from DARPA, goes to the winning M&A winner! https://www.tungstenadv.com/
0 · Reply
alby777
alby777 May. 5 at 5:30 PM
$PFSA Hires Tungsten Advisors for M&A options, https://www.tungstenadv.com/
0 · Reply
alby777
alby777 May. 5 at 5:25 PM
$PFSA Today's Key M&A and Strategic News (May 5, 2026): Strategic Review: The Board is actively seeking to maximize shareholder value, exploring options that include asset-level transactions, commercial partnerships, and business combinations. Financial Advisor: Tungsten Advisors has been engaged as the exclusive strategic financial advisor. https://www.globenewswire.com/news-release/2026/05/05/3287678/0/en/Profusa-Initiates-Board-Led-Process-to-Evaluate-Strategic-Alternatives-and-Maximize-Shareholder-Value.html
0 · Reply